U.S./Japan Free Trade Agreement Would Encourage Pharma Innovation, Lilly CEO Says
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO Taurel argues in favor of an open market that would ease Japan-specific clinical trial requirements.
You may also be interested in...
Japanese Pharmas Need To Get More Global
Japanese firms need to change strategy to become competitive with U.S., European firms, biotech exec says in interview with "The Pink Sheet" DAILY during the BioInvestor Forum in San Francisco.
Japanese Pharmas Need To Get More Global
Japanese firms need to change strategy to become competitive with U.S., European firms, biotech exec says in interview with "The Pink Sheet" DAILY during the BioInvestor Forum in San Francisco.
Japanese Pharmas Need To Get More Global
Japanese pharmaceutical companies need to have a more global reach if they intend to be major players in an increasingly international biotech and pharma market, according to Berkeley, Calif.-based Plexxikon CEO Peter Hirth